A comprehensive surveillance study on the patients with malignant lymphoma undergoing CODOX-M/IVAC regimen with or without rituximab.

A comprehensive surveillance study on the patients with malignant lymphoma undergoing CODOX-M/IVAC regimen with or without rituximab. - A comprehensive surveillance study on the patients with malignant lymphoma undergoing CODOX-M/IVAC regimen with or without rituximab.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000024841

Enrollment

Registered

2016-11-15

Start date

2016-11-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant lymphoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Histological diagnosis of Burkitt lymphoma, Burkitt-like lymphoma in the REAL classification and B-cell lymphoma unclassifiable with features between diffuse large B-cell lymphoma and Burkitt lymphoma in the 2008 WHO lymphoma classification, and primary mediastinal large B-cell lymphoma. 2) Patients treated with CODOX-M/IVAC with or without rituximab as a first-line therapy between 2003 and 2015. 3) In the case of questionnaire investigation, 20 years of age and older in being at commencement of the study.

Exclusion criteria

Exclusion criteria: 1) Patients who have a communication problem in Japanese. 2) Patients who are disqualified by their attending physician. 3) In the case of questionnaire investigation, patients undergoing second-line therapy except for additional radiation therapy for residual lesion after CODOX-M/IVAC with or without rituximab.

Design outcomes

Primary

Measure	Time frame
Evaluation of fertility	—

Secondary

Measure	Time frame
Pregnancy among the patients with fertility preservation, Quality of life (SF-36), Social rehabilitation, Complications, Long-term prognostic analysis	—

Countries

Japan

Contacts

Public ContactKosuke Toyoda

National Cancer Center Hospital Department of Hematology

ktoyoda@ncc.go.jp+81-3-3542-2511

Outcome results